Sutro Biopharma, Inc. - Common Stock, $0.001 par value (STRO)
CUSIP: 869367102
Q2 2025 13F Holders as of 30 Jun 2025
- Type / Class
- Equity / Common Stock, $0.001 par value
- Shares outstanding
- 84,733,230
- Total 13F shares
- 55,585,121
- Share change
- -5,719,376
- Total reported value
- $39,680,994
- Put/Call ratio
- 0%
- Price per share
- $0.71
- Number of holders
- 100
- Value change
- -$3,651,726
- Number of buys
- 52
- Number of sells
- 66
Quarterly Holders Quick Answers
What is CUSIP 869367102?
CUSIP 869367102 identifies STRO - Sutro Biopharma, Inc. - Common Stock, $0.001 par value in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 869367102:
Top shareholders of STRO - Sutro Biopharma, Inc. - Common Stock, $0.001 par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| SUVRETTA CAPITAL MANAGEMENT, LLC |
13F
|
Company |
8.8%
|
7,462,495
|
$4,855,099 | — | 31 Mar 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13D/G
13F
|
Company |
5.6%
|
4,717,215
|
$4,434,182 | $0 | 27 Jun 2025 | |
| BlackRock, Inc. |
13F
13D/G
|
Company |
2.5%
from 13D/G
|
6,204,784
|
$4,036,832 | — | 31 Mar 2025 | |
| Kynam Capital Management, LP |
13F
13D/G
|
Company |
6.4%
from 13D/G
|
5,441,447
|
$3,540,205 | — | 31 Mar 2025 | |
| VANGUARD GROUP INC |
13D/G
13F
|
The Vanguard Group · Company |
4.9%
|
4,115,250
|
$2,937,877 | $0 | 30 Jun 2025 | |
| RA CAPITAL MANAGEMENT, L.P. |
13F
|
Company |
5.2%
|
4,434,637
|
$2,885,175 | — | 31 Mar 2025 | |
| ACADIAN ASSET MANAGEMENT LLC |
13F
|
Company |
3.7%
|
3,134,586
|
$2,037,000 | — | 31 Mar 2025 | |
| Merck & Co., Inc. |
13F
|
Company |
3.2%
|
2,723,509
|
$1,771,915 | — | 31 Mar 2025 | |
| Vestal Point Capital, LP |
13F
|
Company |
3.1%
|
2,600,000
|
$1,691,560 | — | 31 Mar 2025 | |
| Eversept Partners, LP |
13F
|
Company |
2.7%
|
2,292,261
|
$1,491,345 | — | 31 Mar 2025 | |
| Samsara BioCapital, LLC |
13F
|
Company |
2.6%
|
2,196,814
|
$1,429,247 | — | 31 Mar 2025 | |
| William J. Newell |
3/4/5
|
CEO, Director |
—
mixed-class rows
|
768,806
mixed-class rows
|
$1,399,621 | — | 05 Mar 2025 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
|
Company |
2.4%
|
2,000,000
|
$1,301,200 | — | 31 Mar 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
2.2%
|
1,889,272
|
$1,229,393 | — | 31 Mar 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
2%
|
1,712,115
|
$1,113,902 | — | 31 Mar 2025 | |
| STATE STREET CORP |
13F
|
Company |
2%
|
1,682,339
|
$1,094,530 | — | 31 Mar 2025 | |
| AQR CAPITAL MANAGEMENT LLC |
13F
|
Company |
1.6%
|
1,320,917
|
$859,388 | — | 31 Mar 2025 | |
| Velan Capital Investment Management LP |
13F
|
Company |
1.2%
|
1,030,000
|
$670,118 | — | 31 Mar 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
1%
|
868,997
|
$565,369 | — | 31 Mar 2025 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.96%
|
817,479
|
$532,561 | — | 31 Mar 2025 | |
| Trevor Hallam |
3/4/5
|
Pres. Rsrch & Cf. Sctific Ofcr |
—
mixed-class rows
|
107,868
mixed-class rows
|
$507,563 | — | 14 Apr 2023 | |
| Affinity Asset Advisors, LLC |
13F
|
Company |
0.89%
|
752,722
|
$489,721 | — | 31 Mar 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.75%
|
633,923
|
$412,430 | — | 31 Mar 2025 | |
| PRUDENTIAL FINANCIAL INC |
13F
|
Company |
0.71%
|
604,580
|
$393,339 | — | 31 Mar 2025 | |
| Arturo Molina MD |
3/4/5
|
Chief Medical Officer |
—
mixed-class rows
|
127,236
mixed-class rows
|
$354,016 | — | 04 Mar 2022 | |
| DAFNA Capital Management LLC |
13F
|
Company |
0.52%
|
437,079
|
$284,364 | — | 31 Mar 2025 | |
| Shabbir Anik |
3/4/5
|
Chief Technical Ops. Officer |
—
mixed-class rows
|
58,327
mixed-class rows
|
$274,452 | — | 03 Mar 2023 | |
| LPL Financial LLC |
13F
|
Company |
0.46%
|
389,932
|
$253,690 | — | 31 Mar 2025 | |
| Fisher Asset Management, LLC |
13F
|
Company |
0.42%
|
352,949
|
$229,628 | — | 31 Mar 2025 | |
| Venkatesh Srinivasan |
3/4/5
|
CHIEF TECH OP OFFICER |
—
mixed-class rows
|
254,436
mixed-class rows
|
$214,524 | — | 01 May 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.36%
|
301,407
|
$196,095 | — | 31 Mar 2025 | |
| Anne Elizabeth Borgman |
3/4/5
|
CHIEF MEDICAL OFFICER |
—
mixed-class rows
|
115,264
mixed-class rows
|
$195,061 | — | 01 May 2025 | |
| Nuveen, LLC |
13F
|
Company |
0.34%
|
290,897
|
$189,257 | — | 31 Mar 2025 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
0.28%
|
240,900
|
$156,730 | — | 31 Mar 2025 | |
| Edward C. Albini |
3/4/5
|
CFO AND SECRETARY |
0.19%
|
160,805
|
$141,508 | — | 15 May 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.25%
|
209,222
|
$136,120 | — | 31 Mar 2025 | |
| Linda A. Fitzpatrick |
3/4/5
|
CHIEF PEOPLE & COMM. OFFICER |
—
mixed-class rows
|
136,658
mixed-class rows
|
$134,667 | — | 01 May 2025 | |
| Shay Capital LLC |
13F
|
Company |
0.24%
|
205,620
|
$133,776 | — | 31 Mar 2025 | |
| TANG CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.24%
|
200,000
|
$130,120 | — | 31 Mar 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.24%
|
199,901
|
$130,056 | — | 31 Mar 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.23%
|
195,860
|
$127,427 | — | 31 Mar 2025 | |
| AJU IB Investment Co., Ltd. |
13F
|
Company |
0.21%
|
175,000
|
$113,855 | — | 31 Mar 2025 | |
| D. E. Shaw & Co., Inc. |
13F
|
Company |
0.19%
|
158,037
|
$102,819 | — | 31 Mar 2025 | |
| BNP PARIBAS FINANCIAL MARKETS |
13F
|
Company |
0.18%
|
155,235
|
$100,996 | — | 31 Mar 2025 | |
| STRS OHIO |
13F
|
Company |
0.18%
|
152,800
|
$99,412 | — | 31 Mar 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.17%
|
141,229
|
$91,884 | — | 31 Mar 2025 | |
| PANAGORA ASSET MANAGEMENT INC |
13F
|
Company |
0.17%
|
140,362
|
$91,320 | — | 31 Mar 2025 | |
| EXCHANGE TRADED CONCEPTS, LLC |
13F
|
Company |
0.16%
|
136,623
|
$88,887 | — | 31 Mar 2025 | |
| RHUMBLINE ADVISERS |
13F
|
Company |
0.14%
|
122,816
|
$79,943 | — | 31 Mar 2025 | |
| BARCLAYS PLC |
13F
|
Company |
0.14%
|
116,286
|
$75,656 | — | 31 Mar 2025 |
Institutional Holders of Sutro Biopharma, Inc. - Common Stock, $0.001 par value (STRO) as of Q2 2025
As of 30 Jun 2025,
Sutro Biopharma, Inc. - Common Stock, $0.001 par value (STRO) was held by
100 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
55,585,121 shares.
The largest 10 holders included
SUVRETTA CAPITAL MANAGEMENT, LLC, Kynam Capital Management, LP, MILLENNIUM MANAGEMENT LLC, VANGUARD GROUP INC, Velan Capital Investment Management LP, ACADIAN ASSET MANAGEMENT LLC, Merck & Co., Inc., Vestal Point Capital, LP, TANG CAPITAL MANAGEMENT LLC, and Eversept Partners, LP.
This page lists
99
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
113
Q2 2025 holders
100
Holder diff
-13
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 Value $ | Q2 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.